Intelligence · Patents
Patents expiring in 2029
Annual patent cliff calendar for 2029 — US pharmaceutical patents by expiration date.
- Patents
- 675
Quick answer
675 indexed pharmaceutical patents have expiration dates in 2029. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7524507
Recombinant microorganisms
granted -
US 7524499
Modified chimeric polypeptides with improved pharmacokinetic properties
granted -
US 7524880
Crystalline form of a substituted pyrrolidine compound
granted -
US 7527786
Methods for inhibiting the growth of cancer cells expressing PSCA
granted -
US 7528202
Poly (ethylene glycol) derivatives with proximal reactive groups
granted -
US 7528138
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
granted -
US 7527802
Vaccine for transcutaneous immunization
granted -
US 7527934
Labeled substrate conjugates for identifying enzyme inhibitors
granted -
US 7527797
Vibrio cholerae 0139 conjugate vaccines
granted -
US 7528118
RNAi modulation of ApoB and uses thereof
granted -
US 7528253
Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
granted -
US 7528274
Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents
granted -
US 7527952
Crystals of inosine monophosphate dehydrogenase/oxidized inosine monophosphate thiomidate intermediate/mycophenolic acid (IIMPDH/XMP*/MPA)
granted -
US 7528142
Aminopyrimidines useful as kinase inhibitors
granted -
US 7528133
Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
granted -
US 7531523
Sodium channel protein type III alpha-subunit splice variant
granted -
US 7531500
Preventing airway mucus production by administration of EGF-R antagonists
granted -
US 7531536
Pyrazole compounds useful as protein kinase inhibitors
granted -
US 7531556
Compositions useful as inhibitors of rock and other protein kinases
granted -
US 7531570
Treatment of diseases using ICE inhibitors
granted -
US 7531623
Hydrochloride salts of a glycopeptide phosphonate derivative
granted -
US 7531635
MATER-protein specific antibodies and methods of use
granted -
US 7531162
Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
granted -
US 7531656
Synthesis of gatifloxacin
granted -
US 7531341
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
granted -
US 7531514
Orally administered peptides synergize statin activity
granted -
US 7531355
Methods and compositions for smooth muscle reconstruction
granted -
US 7531352
Inducible plasmid vector encoding TGF-β and use thereof
granted -
US 7531173
Ophthalmic composition of a VEGF antagonist
granted -
US 7531172
Methods of treating diseases with a VEGF antagonist
granted -
US 7534418
Imaging agents
granted -
US 7534775
Methods and compositions for modulating cardiac contractility
granted -
US 7534887
Thiazoline derivative and use of the same
granted -
US 7534913
Crystalline form of nateglinide
granted -
US 7534440
Fusion molecules and methods for treatment of immune diseases
granted -
US 7534900
Process for the purification of duloxetine hydrochloride
granted -
US 7534859
Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
granted -
US 7534889
5-HT4 receptor agonist compounds
granted -
US 7534604
Fusion polypeptides capable of activating receptors
granted -
US 7534764
Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
granted -
US 7534761
Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
granted -
US 7534613
Methods of treating parkinson's disease using viral vectors
granted -
US 7534595
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
granted -
US 7534565
DLC-1 gene deleted in cancers
granted -
US 7534868
Human antibodies to human delta like ligand 4
granted -
US 7538125
Pharmaceutical composition
granted -
US 7537791
Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production
granted -
US 7537759
Modulating angiogenesis
granted
Frequently asked questions
How many pharma patents expire in 2029?
675 published patents in our USPTO index have expiration dates falling in calendar year 2029.